High Growth Tech Stocks in the US to Watch for October 2025

As the U.S. market grapples with a mix of earnings reports and renewed U.S.-China trade tensions, major indices like the Nasdaq, Dow Jones Industrial Average, and S&P 500 have recently faced downward pressure. In such a volatile environment, identifying high growth tech stocks requires careful consideration of their resilience to geopolitical issues and their ability to innovate amidst economic challenges.

Click here to see the full list of 72 stocks from our US High Growth Tech and AI Stocks screener.

We’ll examine a selection from our screener results.

Simply Wall St Growth Rating: ★★★★★☆

Overview: Exelixis, Inc. is an oncology-focused company dedicated to discovering, developing, and commercializing new medicines for challenging cancer treatments in the United States, with a market cap of approximately $9.73 billion.

Operations: Exelixis generates revenue primarily from its biotechnology segment, amounting to $2.23 billion. The company is involved in the discovery, development, and commercialization of medicines targeting difficult-to-treat cancers within the U.S.

Exelixis stands out in the biotech sector with its recent STELLAR-303 trial results, indicating a 20% reduction in mortality risk for certain colorectal cancer patients, showcasing its commitment to advancing cancer treatment. The company’s strategic R&D investments are evident as it leverages Adagene’s SAFEbody technology to develop new therapies, highlighting its innovative approach in oncology. Despite a slight dip in quarterly revenue to $568.26 million from $637.18 million last year, Exelixis maintains robust growth prospects with an expected annual earnings increase of 20.8%, underscoring its potential amidst industry challenges.

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Calix, Inc. offers cloud and software platforms along with systems and services across various regions including the United States, the rest of the Americas, Europe, the Middle East, Africa, and Asia Pacific with a market cap of approximately $3.89 billion.

Operations: The company generates revenue primarily from developing, marketing, and selling communications access systems and software, amounting to $869.19 million.

Calix is gearing up for significant growth with its recent innovations in broadband technology, notably through the introduction of SmartBiz and SmartMDU solutions aimed at small businesses and multi-dwelling units. These enhancements are designed to streamline operations and enhance subscriber experiences, crucial in sectors where dependable connectivity is vital. Impressively, Calix has committed over $100 million since November 2023 to evolve its Broadband Platform with agentic AI capabilities, indicating a robust forward-looking strategy. This investment reflects a strategic pivot towards integrating advanced AI to simplify service delivery and operational efficiency—essential for maintaining competitiveness in the rapidly evolving tech landscape. Moreover, these developments have positioned Calix as a pivotal player in supporting broadband service providers by enhancing network management and reliability across increasingly complex environments.

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Phreesia, Inc. offers an integrated SaaS-based software and payment platform tailored for the healthcare industry across the United States and Canada, with a market capitalization of approximately $1.38 billion.

Operations: The company generates revenue primarily through its Technology Solutions segment, which brought in $449.67 million. The platform is designed to streamline operations within the healthcare sector across North America.

Phreesia is making significant strides in the healthcare tech sector, evidenced by a robust annual revenue growth of 10.7% and an impressive forecast for earnings growth at 65.58% per year. The company’s recent launch of Phreesia VoiceAI showcases its commitment to innovation, leveraging advanced AI to enhance patient interaction without increasing staff workload. This move not only supports efficient healthcare delivery but also positions Phreesia well within a competitive landscape that values technological advancement and customer experience. Moreover, their collaboration with Sesame Workshop indicates a strategic approach to engaging younger demographics at the point of care, potentially boosting user engagement and satisfaction.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include EXEL CALX and PHR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com